Real-world data on T-DM1 efficacy – results of a single-center retrospective study of HER2-positive breast cancer patients

• Published in: Scientific reports Vol. 9; no. 1; pp. 12760 - 7
• Main Authors: Hardy-Werbin, Max, Quiroga, Vanesa, Cirauqui, Beatriz, Romeo, Margarita, Felip, Eudald, Teruel, Iris, Garcia, Juan Jose, Erasun, Carlos, España, Sofia, Cucurull, Marc, Montprade, Elisabeth, Pardo, Juan Carlos, Carballo, Dania, Velarde, Jose Maria, Margeli, Mireia
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 04-09-2019; Nature Publishing Group
• Subjects: 631/154; 639/638; Adult; Aged; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Breast Neoplasms - mortality; Central nervous system; Clinical trials; Disease-Free Survival; ErbB-2 protein; Female; Humanities and Social Sciences; Humans; Maytansine - administration & dosage; Metastases; Metastasis; Middle Aged; Monoclonal antibodies; multidisciplinary; Patients; Receptor, ErbB-2 - metabolism; Retrospective Studies; Science; Science (multidisciplinary); Survival; Survival Rate; Targeted cancer therapy; Taxanes; Trastuzumab; Trastuzumab - administration & dosage
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-019-49251-5

T-DM1 is an antibody drug conjugate that combines trastuzumab with emtansine via a stable thioether linker. In two phase III clinical trials, EMILIA and TH3RESA, T-DM1 was shown to be effective in HER2-positive metastatic breast cancer patients who had progressed to taxanes and trastuzumab. We have performed a real-world study to complement the findings of the clinical trials. From 2012 to 2016, 15 patients with HER2-positive breast cancer who had progressed to prior treatment received T-DM1 at our center. We have retrospectively analyzed outcomes in these patients and compared our findings with those of the two clinical trials. Progression-free survival (PFS) was 10 months compared with the 9.6 months of the EMILIA trial and the 6.2 months of the TH3RESA trial, overall survival was 34 months compared with the 29.9 months of the EMILIA trial and the 22.7 months of the TH3RESA trial. PFS was ≥12 months in five patients, three of whom attained a PFS of ≥23 months. Among five patients with metastases of the central nervous system, PFS was six months, OS was not reached, and the objective response rate was 80%. Our findings are in line with those of the EMILIA study and slightly superior to those of the TH3RESA study. In our series of patients, T-DM1 has demonstrated efficacy in the treatment of HER2-positive metastatic breast cancer. Our real-world data thus confirm and support the findings of the two major phase III trials and indicate the usefulness of T-DM1 in routine clinical practice.